HEALTH OF WOMAN. 2020.2(148): 15–20; doi 10.15574/HW.2020.148.15
Nosenko O. M.
Odessa National Medical University, Odessa

The article presents modern literature data on the role of defective deep placentation in the development of great obstetrical syndromes, bioavailable progesterone and its receptors in the formation of the placenta and the development of pregnancy, mechanisms of development of resistance to bioavailable progesterone, and a scheme of the pathogenesis of progesterone deficiency during pregnancy as one of the main causes of great obstetrical syndromes.
Modern data on the development of resistance to bioavailable progesterone in adolescence, in patients with endometrioid disease, polycystic ovary syndrome and idiopathic recurrent pregnancy loss are presented. The therapeutic possibilities of prophylaxis of great obstetrical syndromes with resistance to bioavailable progesterone are described. Research data on the use of highly selective progestogen with increased affinity for progesterone receptors dydrogesterone for the prevention of great obstetrical in pregnant women with resistance to bioavailable progesterone are presented.
Key words: great obstetrical syndromes, defective deep placentation, progesterone, progesterone receptors, bioavailable progesterone resistance, adolescence, endometrioid disease, polycystic ovary syndrome, idiopathic recurrent pregnancy loss, prevention, dydrogesterone.

REFERENCES

1. Voronova II. 2013. ImunologIchnI aspekti nevinoshuvannya vagItnostI rannIh termInIv: dIagnostika, patogenez, lIkuvannya (avtoreferat). Donetsk, Donetskiy natsIonalniy medichniy unIversitet Im. M. Gorkogo:22.

2. Nosenko EN, Zhuk SI, Rutinskaya AV. 2017, berezen-kvIten. Problemnyie voprosy bolshih akusherskih sindromov. Zhіnochiy lіkar:28-35.

3. Fedotcheva TA, Shimanovskiy NL. 2018. Rol gestagenov v lechenii endometrioza. Problemyi endokrinologii 64;1:54-61. https://doi.org/10.14341/probl8742

4. Barbosa MWP, Valadares NPB, Barbosa ACP, Amaral AS, Iglesias JR, Nastri CO et al. 2018, Jun 1. Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis. JBRA Assist Reprod. 22(2):148-156. https://doi.org/10.5935/1518-0557.20180018.

5. Brosens I, Benagiano G. 2015, Oct. Menstrual preconditioning for the prevention of major obstetrical syndromes in polycystic ovary syndrome. Am J Obstet Gynecol. 213(4):488-93. https://doi.org/10.1016/j.ajog.2015.07.021; PMid:26212182.

6. Brosens I, Benagiano G. 2016, Jun. Progesterone Response in Neonatal Endometrium is Key to Future Reproductive Health in Adolescents. Womens Health (Lond) 12(3):279–282. https://doi.org/10.2217/whe-2016-0006; PMid:26880048 PMCid:PMC5384508.

7. Brosens I, Brosens JJ, Muter J, Puttemans P, Benagiano G. 2019. Preeclampsia: the role of persistent endothelial cells in uteroplacental arteries. Clinical opinion. 221(3):219-226. https://doi.org/10.1016/j.ajog.2019.01.239; PMid:30738027

8. Brosens I, Ćurčić A, Vejnović T, Gargett CE, Brosens JJ, Benagiano G. 2015. The perinatal origins of major reproductive disorders in the adolescent: research avenues. Placenta 36(4):341–344. https://doi.org/10.1016/j.placenta.2015.01.003; PMid:25637411

9. Brosens I, Muter J, Gargett CE, Puttemans P, Benagiano G, Brosens JJ. 2017, Nov. The impact of uterine immaturity on obstetrical syndromes during adolescence. Am J Obstet Gynecol. 217(5):546-555. https://doi.org/10.1016/j.ajog.2017.05.059; PMid:28578177.

10. Carp H. 2015, Jun. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol. 31(6):422-30. https://doi.org/10.3109/09513590.2015.1006618; PMid:25765519.

11. ESHRE Guideline Group on RPL, Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S et al. 2018, Apr 6. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open. 2018(2):hoy004. https://doi.org/10.1093/hropen/hoy004; PMid:31486805 PMCid:PMC6276652.

12. Fukui Y, Hirota Y, Matsuo M, Gebril M, Akaeda Sh, Hiraoka T et al. 2019, Jul. Uterine receptivity, embryo attachment, and embryo invasion: Multistep processes in embryo implantation. Reprod Med Biol. 18(3):234–240. https://doi.org/10.1002/rmb2.12280; PMid:31312101 PMCid:PMC6613011.

13. Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C et al. 2019, Feb. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 38(2):249-259. https://doi.org/10.1016/j.rbmo.2018.11.017; PMid:30595525.

14. Joshi NR, Miyadahira EH, Afshar Y, Jeong JW, Young SL, Lessey BA et al. 2017. Progesterone resistance in endometriosis is modulated by the altered expression of microRNA-29c and FKBP4. J Clin Endocrinol Metab. 102:441–9. https://doi.org/10.1210/jc.2016-2076; PMid:27778641 PMCid:PMC5413101

15. Ku CW, Allen JC, Malhotra R, Chong HC, Tan NS, Østbye T et al. 2015. How can we better predict the risk of spontaneous miscarriage among women experiencing threatened miscarriage? Gynecol Endocrinol. 31(8):647-51. https://doi.org/10.3109/09513590.2015.1031103; PMid:26036717.

16. Labarrere CA, DiCarlo HL, Bammerlin E, Hardin JW, Kim YM, Chaemsaithong P et al. 2017, Mar. Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta. Am J Obstet Gynecol. 216(3):287.e1–287.e16. https://doi.org/10.1016/j.ajog.2016.12.029; PMid:28034657 PMCid:PMC5881902.

17. Lee HJ, Park TC, Kim JH, Norwitz E, Lee B. 2017. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. Biomed Res Int 2017:3616875. https://doi.org/10.1155/2017/3616875; PMid:29392134 PMCid:PMC5748117.

18. Li X, Feng Y, Lin J-F, Billig H, Shao R. 2014. Endometrial progesterone resistance and PCOS. J Biomed Sci. 21(1):2. https://doi.org/10.1186/1423-0127-21-2; PMid:24405633 PMCid:PMC3917599.

19. Lim MK, Ku ChW, Tan ThCh, Lee YHJ, Allen JC, Tan NS. 2020. Characterisation of serum progesterone and progesterone-induced blocking factor (PIBF) levels across trimesters in healthy pregnant women. Sci Rep. 10:3840. https://doi.org/10.1038/s41598-020-59452-y; PMid:32123187 PMCid:PMC7051977.

20. Lucas ES, Vrljicak P, Muter J, Diniz-da-Costa MM, Brighton PJ, Kong Sh-S et al. 2020. Recurrent pregnancy loss is associated with a pro-senescent decidual response during the peri-implantation window. Commun Biol. 3:37. https://doi.org/10.1038/s42003-020-0763-1; PMid:31965050 PMCid:PMC6972755.

21. Maliqueo M, Echiburú B, Crisosto N. 2016, Apr 26. Sex Steroids Modulate Uterine-Placental Vasculature: Implications for Obstetrics and Neonatal Outcomes. Front Physiol. 7:152. https://doi.org/10.3389/fphys.2016.00152; PMid:27199767 PMCid:PMC4844620.

22. Nosenko OM, Kosyuga OM. 2019. Evaluation of the effect of different methods of curacy on women with adenomyosis in the first half of pregnancy on the development of early gestative complications. Journal of Education, Health and Sport. 9(5):709-720. doi: http://dx.doi.org/10.5281/zenodo.3612163 http://ojs.ukw.edu. pl/index.php/ johs/article/view/7672.

23. Pabalan N, Salvador A, Jarjanazi H, Christofolini DM, Barbosa CP, Bianco B. 2014. Association of the progesterone receptor gene polymorphism (PROGINS) with endometriosis: a meta-analysis. Arch Gynecol Obstet. 290:1015–22. https://doi.org/10.1007/s00404-014-3308-3; PMid:24943061

24. Patel B, Elguero S, Thakore S, Dahoud W, Bedaiwy M, Mesiano S. 2015, Mar. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 21(2):155–173. https://doi.org/10.1093/humupd/dmu056; PMid:25406186 PMCid:PMC4366574.

25. Patel BG, Rudnicki M, Yu J, Shu Y, Taylor RN. 2017, Jun. Progesterone resistance in endometriosis: origins, consequences and interventions. Acta Obstet Gynecol Scand. 96(6):623-632. https://doi.org/10.1111/aogs.13156; PMid:28423456.

26. Pollheimer J, Vondra S, Baltayeva J, Beristain AG, Knöfler M. 2018. Regulation of Placental Extravillous Trophoblasts by the Maternal Uterine Environment. Front Immunol. 9:2597. https://doi.org/10.3389/fimmu.2018.02597; PMid:30483261 PMCid:PMC6243063.

27. Puttemans P, Benagiano G, Gargett C, Romero R, Guo S-W, Brosens I. 2017, Jun. Neonatal uterine bleeding as a biomarker for reproductive disorders during adolescence: a worldwide call for systematic registration by nurse midwife. J Matern Fetal Neonatal Med. 30(12):1434–1436. https://doi.org/10.1080/14767058.2016.1216540; PMid:27454348 PMCid:PMC5505234.

28. Rana S, Lemoine E, Granger JP, Karumanchi SA. 2019, Mar 29. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 124(7):1094-1112. https://doi.org/10.1161/CIRCRESAHA.118.313276; PMid:30920918.

29. Recurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050) Geburtshilfe Frauenheilkd. 2018, Apr. 78(4):364–381. https://doi.org/10.1055/a-0586-4568; PMid:29720743 PMCid:PMC5925690.

30. Romero R, Kusanovic JP, Chaiworapongsa T, Hassan SS. 2011, Jun. Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. Best Pract Res Clin Obstet Gynaecol. 25(3):313–327. https://doi.org/10.1016/j.bpobgyn.2011.02.006; PMid:21388889 PMCid:PMC3092823

31. Saccone G, Schoen C, Franasiak JM, Scott RT Jr, Berghella V. 2017. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 107(2):430–438 e433. https://doi.org/10.1016/j.fertnstert.2016.10.031; PMid:27887710.

32. Schindler AE, Carp H, Druckmann R, Genazzani AR, Huber J, Pasqualini J et al. 2015. European Progestin Club Guidelines for prevention and treatment of threatened or recurrent (habitual) miscarriage with progestogens. Gynecol Endocrinol. 31(6):447–449. https://doi.org/10.3109/09513590.2015.1017459; PMid:25976550.

33. Schindler AE. 2017. A brief guideline proposal for using dydrogesterone prevention or treatment of pregnancy disorders. J Pregnancy Reprod. 1(4):1-3. https://doi.org/10.15761/JPR.1000122.

34. Soares MJ, Varberg KM, Iqbal Kh. 2018, Jul. Hemochorial placentation: development, function, and adaptations†Biol Reprod. 99(1):196–211. https://doi.org/10.1093/biolre/ioy049; PMid:29481584 PMCid:PMC6044390.

35. Szekeres-Bartho J, Šućurović S, Mulac-Jeričević B. 2018. The Role of Extracellular Vesicles and PIBF in Embryo-Maternal Immune-Interactions. Front Immunol. 9:2890. https://doi.org/10.3389/fimmu.2018.02890; PMid:30619262 PMCid:PMC6300489.

36. Wang A, Rana S, Karumanchi SA. 2009. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 24:147-58. https://doi.org/10.1152/physiol.00043.2008; PMid:19509125

37. Zainul Rashid MR, Lim JF, Nawawi NH, Luqman M, Zolkeplai MF, Rangkuty HS et al. 2014. A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in primigravidae. Gynecological Endocrinology. 30(3):217–220. https://doi.org/10.3109/09513590.2013.860960; PMid:24552449.

38. Zarean E, Mostajeran F, Dayani Z. 2018. Effect of Dydrogesterone on the Outcome of Idiopathic Intrauterine Growth Restriction: A Double-blind Clinical Trial Study. Adv Biomed Res. 7:93. https://doi.org/10.4103/abr.abr_250_16; PMid:30050881 PMCid:PMC6036772.